Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
CYPRESS BIOSCIENCE INC (CYPB)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 02/08/2012 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/14/2011 |
SC 13G/A
| MAVERICK CAPITAL LTD reports a 0% stake in CYPRESS BIOSCIENCE, INC. |
| 02/14/2011 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/11/2011 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals |
| 02/04/2011 |
SC 13G/A
| CYPRESS BIOSCIENCE INC reports a 7% stake in CYPRESS BIOSCIENCE INC |
| 01/19/2011 |
EFFECT
| Form EFFECT - Notice of Effectiveness |
| 01/19/2011 |
EFFECT
| Form EFFECT - Notice of Effectiveness |
| 01/19/2011 |
EFFECT
| Form EFFECT - Notice of Effectiveness |
| 01/19/2011 |
EFFECT
| Form EFFECT - Notice of Effectiveness |
| 01/13/2011 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities |
| 01/06/2011 |
SC TO-T/A
| Form SC TO-T - Tender offer statement by Third Party [amend] |
| 01/04/2011 |
MW
| FTC Grants Early Termination of Waiting Period Under Hart-Scott-Rodino Act |
| 12/29/2010 |
4
| KRANZLER JAY D (CEO) has filed a Form 4 on CYPRESS BIOSCIENCE INC|
Txns:
| Exercised 25,000 shares
@ $3.25, valued at
$81.3k
Sold 25,000 shares
@ $6.46, valued at
$161.5k
Exercised 25,000 options to buy
@ $3.25, valued at
$81.3k
|
|
| 12/29/2010 |
4
| KRANZLER JAY D (CEO) has filed a Form 4 on CYPRESS BIOSCIENCE INC|
Txns:
| Exercised 152,464 shares
@ $3.25, valued at
$495.5k
Sold 152,464 shares
@ $6.45, valued at
$983.4k
Exercised 152,464 options to buy
@ $3.25, valued at
$495.5k
|
|
| 12/23/2010 |
SC 13D
| CYPRESS BIOSCIENCE INC reports a 9.9% stake in CYPRESS BIOSCIENCE, INC. |
| 12/22/2010 |
8-K
| Quarterly results |
| 12/21/2010 |
4
| Srinivas Rao (Chief Scientific Officer) has filed a Form 4 on CYPRESS BIOSCIENCE INC|
Txns:
| Sold 7,500 shares
@ $6.44, valued at
$48.3k
Exercised 7,500 options to buy
@ $4.75, valued at
$35.6k
|
|
| 12/21/2010 |
SC TO-T/A
| Form SC TO-T - Tender offer statement by Third Party [amend] |
| 12/20/2010 |
SC 13D/A
| CYPRESS BIOSCIENCE INC reports a 9.9% stake in Cypress Bioscience, Inc. |
| 12/16/2010 |
8-K
| Entry into a Material Definitive Agreement, Material Modifications to Rights of Security Holders, Financial Statements and Ex...|
Docs:
|
"Agreement and Plan of Merger, by and among Cypress Bioscience, Inc., Ramius Value and Opportunity Advisors LLC, Royalty Pharma US Partners, LP, Royalty Pharma US Partners 2008, LP, RP Investment Corp. and Ramius V&O Acquisition LLC",
"Amendment No. 1 to Rights Agreement, by and among Cypress Bioscience, Inc. and American Stock Transfer & Trust Company, LLC, as rights agent" |
|
| 12/15/2010 |
SC TO-T/A
| Form SC TO-T - Tender offer statement by Third Party [amend] |
| 12/15/2010 |
8-K
| Form 8-K - Current report |
| 12/15/2010 |
BW
| Cypress Bioscience Agrees To Be Acquired by Ramius LLC and Royalty Pharma for $6.50 Per Share in Cash |
| 12/14/2010 |
SC TO-T/A
| Form SC TO-T - Tender offer statement by Third Party [amend] |
| 12/10/2010 |
SC TO-T/A
| Form SC TO-T - Tender offer statement by Third Party [amend] |
| 12/10/2010 |
BW
| Cypress Bioscience Board of Directors Confirms Receipt of Revised Ramius LLC Offer in Connection with Strategic Review Process |
| 11/09/2010 |
10-Q
| Quarterly Report for the period ended September 30, 2010 |
| 11/09/2010 |
8-K
| Form 8-K - Current report |
| 11/09/2010 |
MW
| Cypress Bioscience Announces Third Quarter 2010 Financial Results |
| 11/03/2010 |
MW
| Cypress Bioscience, Inc. to Present at Oppenheimer 21st Annual Healthcare Conference |
| 10/12/2010 |
SC TO-T/A
| Form SC TO-T - Tender offer statement by Third Party [amend] |
| 10/08/2010 |
8-K
| Form 8-K - Current report |
| 09/30/2010 |
SC 13D/A
| CYPRESS BIOSCIENCE INC reports a 2.6% stake in Cypress Bioscience, Inc. |
| 09/28/2010 |
MW
| Cypress Bioscience Board of Directors Unanimously Rejects Ramius' Unsolicited Tender Offer |
|
|
|